Network meta-analysis reveals comparative outcomes of pooled prasugrel doses in acute coronary syndrome, indicating significant trade-offs between efficacy and bleeding.
Key Points
To evaluate the comparative clinical efficacy and safety of pooled prasugrel dosing strategies compared with other P2Y12 inhibitors.
Conducted a network meta-analysis synthesizing evidence from randomized clinical trials evaluating prasugrel dosing regimens.
Compared pooled dose strategies against alternative P2Y12 receptor antagonist regimens across ischemic and safety endpoints.
Assessed comparative ischemic and hemorrhagic risks across pooled prasugrel regimens and competing antiplatelet therapies qualitatively.
Demonstrated dose-dependent variations in cardiovascular protection and bleeding complications across the analyzed treatment network.